PE Receives Approval for New CPT Codes from AMA

9 March 2018
Company Announcement


PACIFIC EDGE RECEIVES APPROVAL FOR NEW CPT CODES FROM AMA

Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), advises that the American Medical Association (AMA)
Current Procedural Terminology (CPT®) Editorial Panel has granted Administrative MAAA CPT codes for Pacific
Edge’s Cxbladder Detect and Cxbladder Monitor tests.
The granting of these dedicated codes is a key component of the reimbursement process in the US and will help
with access to the Cxbladder tests for urologists and their patients across the United States.
“The CPT Category Administrative MAAA code approval is recognition by the leading panel of medical experts in
the United States that the Cxbladder tests are now established diagnostic tests addressing an important unmet
medical need,” said Jackie Walker, CEO of Pacific Edge Diagnostics USA Ltd.
“The multiple peer-reviewed clinical studies and the growing adoption of the tests in the United States were key
factors in the decision by the CPT Editorial Board reviewers.”
CEO of Pacific Edge, David Darling, commented: “This positive reimbursement code award continues to reflect the
growing acceptance of Cxbladder as effective, non-invasive and highly accurate tests for the detection and
improved management of urothelial cancer. Having unique codes in place will facilitate reimbursement for
Cxbladder in the US, minimising barriers for urologists who order Cxbladder tests for their patient care.”
For more information contact:

David Darling
Chief Executive Officer
Pacific Edge Ltd
P: +64 (3) 479 5800

OVERVIEW www.pacificedge.co.nz www.pacificedgedx.com
Pacific Edge Limited (NZX: PEB) is a New Zealand publicly listed, cancer diagnostic company specialising in the discovery and
commercialisation of diagnostic and prognostic tests for better detection and management of cancer. Its Cxbladder suite of
non-invasive, simple to use and accurate diagnostic tests provide actionable results, and better detection and management of
urothelial cancer. The company is developing and commercialising its range of Cxbladder bladder cancer tests globally through
its wholly owned central laboratories in New Zealand and the USA. The company’s products have been tested and validated in
international multi-centre clinical studies.

ABOUT Cxbladder Triage www.cxbladder.com
Cxbladder Triage combines the power of the genomic biomarkers with additional phenotypic and clinical risk factors to
accurately identify patients with haematuria who have a low probability of bladder cancer and may not require a more
extensive urological evaluation. Cxbladder Triage is a tool for use by clinicians and physicians in primary evaluation of patients
with haematuria and is intended to reduce the need for an expensive and invasive work-up in patients who have a low
probability of having urothelial carcinoma.

ABOUT Cxbladder Detect www.cxbladder.com
Cxbladder Detect enables the non-invasive detection of bladder and other urinary tract cancers from a small volume of a
patients’ urine. Cxbladder Detect provides clinicians with a quick, cost effective and accurate measure of the presence of the
cancer as an effective adjunct to cystoscopy.

9 March 2018
Company Announcement

ABOUT Cxbladder Monitor www.cxbladder.com
Cxbladder Monitor allows urologists to monitor bladder cancer patients for recurrence of the disease. Bladder cancer has a
recurrence rate of 50-80% and requires life-long surveillance. Cxbladder Monitor accurately identifies patients with a prior
history of urothelial cancer (UC) whose Cxbladder Monitor score shows that they have a low probability of recurrent urothelial
carcinoma. Cxbladder Monitor is designed to be used as the preferred adjunct test to cystoscopy in the management of patients
for ongoing evaluation of recurrent bladder cancer.

ABOUT Cxbladder Resolve www.cxbladder.com
Cxbladder Resolve identifies those patients who are likely to have aggressive or more advanced bladder cancer. Cxbladder
Resolve, when used as part of the primary evaluation of haematuria and/or in conjunction with other Cxbladder tests (Triage,
Detect), is designed to assist clinicians by accurately identifying patients with a high probability of having high grade or late
stage bladder cancer, for whom alternative or expedited treatment options may be warranted, or who can be prioritised for
further investigation in high throughput settings.


Refer to www.cxbladder.com for more information.